PELTHOS THERAPEUTICS INC
PTHSNYSE AMERICAN🏆 #3076 by market capUS Equity
$379.35▲ $20.11 (+5.30%)
Simulated price1h—
24h▲ 5.3%
7d—
14d—
30d—
1y—
🏦Market Cap
$100M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
—
Otter Score
60
Fair
No chart data available for PTHS.
Trading Snapshot
- Day Range
- $377.74 – $381.07
- 52-Week Range
- $11.20 – $54.29
- Volume
- $1.72B
- Avg Volume
- $2.12B
- Shares Outstanding
- 3.5M
- Next Earnings
- Oct 1, 2026
Fundamentals Snapshot
- Annual Revenue
- $16M
- Last Q Revenue
- $4M
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- $-20.59
- Dividend Yield
- —
Why Investors Own PTHS
- ✓High-growth profile — revenue up +32.9% YoY with expanding US Equity exposure.
- ✓Healthy economics — 49% gross margin and 29% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
Revenue (TTM)
$16M▲ +36.1% YoY
Gross Margin (TTM)
48.9%▲ +3.7% YoY
Operating Income (TTM)
$4M▲ +36.1% YoY
Free Cash Flow (TTM)
$5M▲ +36.1% YoY
About PELTHOS THERAPEUTICS INC
A company profile for PELTHOS THERAPEUTICS INC isn’t available yet — check back soon.
🦦
Otter Score Breakdown
ⓘ💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
Overall Score
Fair
60/100
Analyst Price Target
ⓘAverage Target
$383.99
▲ +1.2% Upside
High Target$474.48
Low Target$329.28
Based on 21 analysts
Latest News & Updates
🚀
Barron’s·2h ago
PELTHOS THERAPEUTICS INC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
🛰️
Reuters·5h ago
Analysts lift PTHS price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
🌌
MarketWatch·1d ago
PELTHOS THERAPEUTICS INC announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.